ERBB2 and gastroesophageal junction adenocarcinoma: The study enrolled patients with advanced G/GEJ adenocarcinoma who had previously received treatment for HER2 overexpression (IHC 3+ or 2+) and were treated with a combination of vidisitmab and a PD-1 inhibitor.